ORYZON selected as Associated Partner in the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

  • Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain
  • Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, May 29th, 2024 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today a public approval from the EU Commission, under EU State aid rules, of the first Important Project of Common European Interest (IPCEI) to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals (https://ec.europa.eu/commission/presscorner/detail/en/ip_24_2852). The Member States will provide up to €1 billion in public funding, which is expected to unlock an additional €5.9 billion in private investments.

Oryzon has been selected to participate as an Associated Partner in the Consortium. The Med4Cure is a macro-project that deploys 14 scientific projects to be developed by 13 companies as Direct Partners and 11 as Associated Partners. The project to be developed by Oryzon is called VANDAM and aims to validate epigenetic experimental drugs by applying a personalized medicine approach for rare and orphan diseases.

Spain included its participation in the IPCEI Med4Cure in the Recovery and Resilience Plan and has the possibility to partly fund its projects through the Recovery and Resilience Facility.

More information on the amount of aid to individual participants will be available in the public version of the Commission's decision, once confidentiality issues have been resolved with Member States and third parties.

Dr. Carlos Buesa, CEO of Oryzon stated, “We would like to manifest our public gratitude to the EU officials and the Governmental agency CDTI in Spain for their support and collaborative work.” Dr. Buesa continued, “This multinational EU project will play a critical role to ensure access to European citizens and future global generations of the best innovative medicines in Precision Medicine of Rare diseases. This is a first communication for transparency. We will provide more details on our project activities, budget and the State-Aid that we have been granted once confidentiality issues have been resolved with Member States and third parties.”

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets like HDAC-6, where ORY-4001 has been nominated as clinical candidate for the treatment of certain neurological disorders such as CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com


This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.